NCT04877275 2023-12-06
ATG-010(Selinexor) in Combination With Chemotherapy in RRMM
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
Clinical Trials
13 trialsNCT00074490 2018-12-31
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01215344 2018-05-15
First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT00837200 2017-07-24
Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies
Milton S. Hershey Medical Center
Phase 2 Terminated
NCT00148317 2017-07-18
Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma
Weill Medical College of Cornell University
Phase 2 Completed
NCT00222105 2017-07-02
A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life
University of Kansas Medical Center
Phase 2 Completed
NCT00201695 2015-06-10
Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00706953 2015-04-06
A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Withdrawn
NCT01078441 2015-01-12
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00617591 2014-01-17
Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01492881 2012-05-11
Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Withdrawn
NCT00116961 2012-02-07
Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT01328236 2011-09-22
Bortezomib
Clinical Service, China
Phase 2 Unknown